Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
15.897 / 17.034
#127169

Re: Farmas USA

Si, COVID y no COVID. Todo en uno
#127170

Re: Farmas USA

No me dejes solo en AUPH :) a ver si arrancan ya...

La verdad es que dan ganas de largarlas, no se mueven casi, en fin
#127172

Re: Farmas USA

Si, se quien es Elon musk y todo lo que hace. Lo que me interesaba es lo que dice el artículo sobre Ese servicio de tradingCon IA
#127174

Re: Farmas USA

Buena entrada, pillado el dip, de -10% a verde
A parte del variado portfolio, es interesante la fabricación de saponinas necesarias para fabricar las vacunas COVID 
AGEN
#127175

Re: Farmas USA

Os acompaño a 5,13 un poquito mas caras pero seguro que no comprasteis para vender en mi precio jeje, suerte !!
Agen 
#127176

Re: Farmas USA

TGTX +11%

TG Therapeutics climbs after FDA approval for Ukoniq

Feb. 05, 2021 1:51 PM ETTG Therapeutics, Inc. (TGTX)By: Dulan Lokuwithana, SA News Editor12 Comments
  • TG Therapeutics (NASDAQ:TGTX) has surged ~6.1% after the FDA announced the approval for Ukoniq (umbralisib) for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20 based regimen.
  • The approval is also granted for Ukoniq in the treatment of adult patients with relapsed or refractory follicular lymphoma who have undergone at least three prior lines of systemic therapy.
  • In August, TG Therapeutics announced that the regulator accepted the marketing application for the therapy in MZL under the priority review status setting an FDA action date of February 15, 2021. With a standard review, the FL indication had a PDUFA goal date of June 15, 2021
  • The new drug application was supported by umbralisib monotherapy MZL and FL cohorts in a Phase 2b trial evaluating patients with relapsed/refractory MZL or FL.